Claims for Patent: 10,350,306

Summary for Patent: 10,350,306

Title:	Methods and compositions for treating genetically linked diseases of the eye
Abstract:	Expression vectors and therapeutic methods of using such vectors in the treatment of diseases of the eye resulting from failure to produce a specific protein in the eye, or the production of a non-functional protein in the eye.
Inventor(s):	Sieving; Paul Albert (Bethesda, MD), Bush; Ronald Avery (Gaithersburg, MD), Colosi; Peter C. (San Anselmo, CA), Zeng; Yong (Potomac, MD)
Assignee:	The United States of America, as represented by the Secretary, Dept. of Health and Human Services (Washington, DC)
Application Number:	15/876,821
Patent Claims:	1. A method of treating X linked retinoschisis (XLRS) in a human comprising: administering to a human subject diagnosed with XLRS by intravitreal or subretinal injection, a therapeutically effective amount of an AAV2 or AAV8 expression vector comprising: an expression cassette comprising an eye-specific promoter operably-linked to a nucleic acid sequence encoding a retinoschisin gene, including at least a 319-base pair portion of the first intron of the retinoschisin gene, wherein administration of the expression vector causes expression of a human retinoschisin protein in a retinal cell of the human subject, and reduces at least one symptom of XLRS in the subject. 2. The method of claim 1, wherein the vector is administered by intravitreal injection. 3. The method of claim 1, wherein the expression vector is administered by intravitreal injection from a polypropylene syringe. 4. The method of claim 1, wherein the expression vector is administered subretinally. 5. The method of claim 1, wherein the expression vector is administered at a dose between about 3e.sup.8 vg/eye to about 1e.sup.13 vg/eye. 6. The method of claim 1, wherein the expression vector is administered at a dose between about 1e.sup.10 vg/eye to about 1e.sup.13 vg/eye. 7. The method of claim 1, wherein the method further comprises administering the expression vector in combination with one or more additional active agents or supportive therapies for treating, preventing, or reducing the severity of XLRS in the subject. 8. The method of claim 7, wherein the one or more supportive therapies is selected from the group consisting of: surgery, photocoagulation, anti-angiogenic therapy, bevacizumab, ranibizumab, and Aflibercept, flunarizine and nifedipine, cryotherapy, hyperbaric oxygenation, topiramate, MK-801, dextromethorphan, eliprodil, and flupirtine, dimethylthiourea, alpha-lipoic acid, superoxide dismutase, catalase, desferrioxamine, mannitol, allopurinol, calcium dobesilate, flupirtine, trimetazidine, anti-inflammatory agents, cyclodiathermy, cyclocryotherapy, ocular filtering procedures, implantation of drainage valves, aspirin, ticlopidine, clopidogrel, warfarin and heparin, steroids, systemic or local corticosteroids, dexamethasone, cyclosporine, azathioprine, cyclophosphamide, mycophenolate, mofetil, infliximab and etanercept, vitamin C, vitamin E, lutein, zinc, folic acid, vitamin B6, vitamin B12, vitamin D, calcium, zeaxanthin, vitrectomy, scleral buckle surgery, pneumatic retinopexy, ciliary neurotrophic factor (CNTF) protein, brain-derived neurotrophic factor (BDNF) protein, pigment epithelium-derived factor (PEDF) protein, and lens epithelial derived growth factor (LEDGF). 9. The method of claim 7, wherein the expression vector is administered concurrently with a corticosteroid and a steroid-sparing immunosuppressant. 10. The method of claim 7, wherein the expression vector is administered concurrently with an anti-inflammatory agent selected from the group consisting of cyclosporine, mycophenolate mofetil, prednisone, and combinations thereof. 11. The method of claim 10, wherein the administration of the anti-inflammatory agent is initiated prior to the day of administration of the expression vector. 12. The method of claim 10, wherein the administration of the anti-inflammatory agent continues for at least 30 days after the administration of the expression vector. 13. The method of claim 7, wherein the expression vector is administered concurrently with a steroidal anti-inflammatory compound and a combination of calcium and Vitamin D supplements.

Details for Patent 10,350,306

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2033-02-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2033-02-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2033-02-15
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2033-02-15